Markets moved on two fronts: a vaccine trial success lifted biotech sentiment, while a major chipmaker's financing maneuver signaled confidence in deal-making despite elevated rates. Tech and healthcare diverged on fundamentals rather than macro.

• Moderna stock doubles on cancer vaccine Phase 3 trial results
• Broadcom raises billions in debt to fund chip acquisition
• Samsung announces shareholder returns including third-quarter dividend

Sources: MarketWatch, Decrypt, CNBC, Cointelegraph, The Block, The Defiant, CoinDesk

This article is for information only and is not financial advice.